Genmab Closes $2.5 Billion Notes Offering to Fund Merus Acquisition
Genmab A/S has closed a $2.5 billion notes offering, raising $1.5 billion through 6.250% senior secured notes due 2032 and $1.0 billion through 7.250% senior unsecured notes due 2033. The proceeds will finance the acquisition of Merus N.V. and cover related expenses.
Genmab A/S has completed the closing of a previously announced private offering, raising $1.5 billion through 6.250% senior secured notes due 2032 and $1.0 billion through 7.250% senior unsecured notes due 2033. The company plans to use the proceeds from this offering, along with funds from new credit facilities and cash on hand, to finance the pending acquisition of Merus N.V. and cover related fees and expenses. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001142806-en) on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
